IgG4相关肾病的临床与预后因素
一项来自欧洲两国35个中心的观察性队列研究纳入101例IgG4相关肾病患者,中位随访24个月。器官受累数和低补体C3/C4与复发风险升高独立相关,利妥昔单抗一线治疗与较低复发风险相关,血清IgG4≥5 g/L与更严重慢性肾脏病独立相关。
要点
- 器官受累数(HR 1.26)和低补体C3/C4(HR 2.31)与复发风险升高独立相关。
- 利妥昔单抗一线治疗与较低复发风险独立相关(HR 0.22)。
- 血清IgG4≥5 g/L与末次随访eGFR≤30独立相关(OR 4.46)。
核心结论
- IgG4相关肾病主要累及中年男性,表现为小管间质性肾炎,可能伴肾小球受累。
- 补体消耗和器官受累数与较高复发率相关,利妥昔单抗一线治疗与较低复发率相关。
- 血清IgG4浓度高(≥5 g/L)的患者肾脏病更严重。
研究设计与样本
- 观察性队列研究,使用来自欧洲两国35个中心的数据。
- 从医疗记录中收集临床、生物学、影像学和组织病理学数据、治疗方式及结局。
- 共纳入101例成人IgG4相关疾病患者,中位随访24(11-58)个月。
主要发现
- 87例(86%)为男性,中位年龄68(57-76)岁。
- 83例(82%)经肾活检确诊IgG4相关肾病,所有活检均显示小管间质受累,16例显示肾小球病变。
- 90例(89%)接受糖皮质激素治疗,18例(18%)接受利妥昔单抗作为一线治疗。
- 末次随访时32%的患者eGFR低于30 ml/min per 1.73 m²;34例(34%)患者经历复发,12例(13%)患者死亡。
- 末次随访时19例(19%)患者eGFR≤30 ml/min per 1.73 m²。
关键数值与推荐
- Cox生存分析:器官受累数(HR 1.26;95%CI 1.01至1.55)和低C3及C4浓度(HR 2.31;95%CI 1.10至4.85)与较高复发风险独立相关。
- 利妥昔单抗一线治疗与较低复发风险独立相关(HR 0.22;95%CI 0.06至0.78)。
- Logistic回归:年龄(OR 1.11;95%CI 1.03至1.20)、峰值血清肌酐(OR 2.74;95%CI 1.71至5.47)和血清IgG4水平≥5 g/L(OR 4.46;95%CI 1.23至19.40)为严重CKD的独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IgG4-related kidney disease is a major manifestation of IgG4-related disease, a systemic fibroinflammatory disorder. However, the clinical and prognostic kidney-related factors in patients with IgG4-related kidney disease are insufficiently defined. METHODS: We conducted an observational cohort study using data from 35 sites in two European countries. Clinical, biologic, imaging, and histopathologic data; treatment modalities; and outcomes were collected from medical records. Logistic regression was performed to identify the possible factors related to an eGFR ≤30 ml/min per 1.73 m 2 at the last follow-up. Cox proportional hazards model was performed to assess the factors associated with the risk of relapse. RESULTS: We studied 101 adult patients with IgG4-related disease with a median follow-up of 24 (11-58) months. Of these, 87 (86%) patients were male, and the median age was 68 (57-76) years. Eighty-three (82%) patients had IgG4-related kidney disease confirmed by kidney biopsy, with all biopsies showing tubulointerstitial involvement and 16 showing glomerular lesions. Ninety (89%) patients were treated with corticosteroids, and 18 (18%) patients received rituximab as first-line therapy. At the last follow-up, the eGFR was below 30 ml/min per 1.73 m 2 in 32% of patients; 34 (34%) patients experienced a relapse, while 12 (13%) patients had died. By Cox survival analysis, the number of organs involved (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.01 to 1.55) and low C3 and C4 concentrations (HR, 2.31; 95% CI, 1.10 to 4.85) were independently associated with a higher risk of relapse, whereas first-line therapy with rituximab was protective (HR, 0.22; 95% CI, 0.06 to 0.78). At their last follow-up, 19 (19%) patients had an eGFR ≤30 ml/min per 1.73 m 2 . Age (odd ratio [OR], 1.11; 95% CI, 1.03 to 1.20), peak serum creatinine (OR, 2.74; 95% CI, 1.71 to 5.47), and serum IgG4 level ≥5 g/L (OR, 4.46; 95% CI, 1.23 to 19.40) were independently predictive for severe CKD. CONCLUSIONS: IgG4-related kidney disease predominantly affected middle-aged men and manifested as tubulointerstitial nephritis with potential glomerular involvement. Complement consumption and the number of organs involved were associated with a higher relapse rate, whereas first-line therapy with rituximab was associated with lower relapse rate. Patients with high serum IgG4 concentrations (≥5 g/L) had more severe kidney disease.
引用
- Chaba A, Devresse A, Audard V, et al. Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease. Clin J Am Soc Nephrol. 2023. PMID: 37283461. doi:10.2215/CJN.0000000000000193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。